FRESENIUS SE+CO.KGAA O.N.
FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
FRE
6/27/2022 9:45:07 PM
|
Chg.
+0.710
|
Volume |
Bid9:59:15 PM |
Ask9:59:15 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
28.900EUR
|
+2.52%
|
58,425 Turnover: 1.68 mill. |
28.650Bid Size: 1,553 |
28.900Ask Size: 3,720 |
16.07 bill.EUR |
3.20% |
8.83 |
Business description
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Management board & Supervisory board
CEO |
Stephan Sturm |
Management board |
Rachel Empey (bis 31.08.2022), Sara Hennicken (ab 1.09.2022), Dr. Ernst Wastler, Dr. Francesco De Meo, Michael Sen, Rice Powell, Sebastian Biedenkopf |
Supervisory board |
Wolfgang Kirsch, Grit Genster, Michael Diekmann, Bernd Behlert, Frauke Lehmann, Klaus-Peter Müller, Konrad Kölbl, Oscar Romero De Paco, Prof. Dr. D. Michael Albrecht, Prof. Dr. Iris Löw-Friedrich, Stefanie Balling, Susanne Zeidler |
Company data
Name: |
Fresenius SE & Co. KGaA |
Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
Phone: |
+49-6172-608-0 |
Fax: |
- |
E-mail: |
pr-fre@fresenius.com
|
Internet: |
www.fresenius.de |
Industry: |
Healthcare |
Sector: |
Medical Products |
Sub sector: |
Advanced Medical Devices |
End of financial year: |
12/31 |
Free Float: |
56.49% |
IPO date: |
12/18/1986 |
Investor relations
Name: |
Markus Georgi |
IR phone: |
+49-6172-608-2485 |
IR Fax: |
+49-6172-608-2488 |
IR e-mail: |
ir-fre@fresenius.com
|
Company calendar
CW 32 | 8/2/2022
Interim Report 2nd Quarter/6 Months
|
CW 45 | 11/1/2022
Interim Report 3rd Quarter/9 Months
|
Main Shareholders
Freefloat |
|
56.49% |
Else Kröner-Fresenius-Stiftung |
|
27.00% |
BlackRock, Inc. |
|
4.74% |
Allianz Global Investors GmbH |
|
2.98% |
DWS Investment GmbH |
|
2.98% |
The Capital Group Companies, Inc. |
|
2.92% |
Henderson Group plc |
|
2.89% |